Pfizer Inc. $PFE Shares Acquired by ProShare Advisors LLC

ProShare Advisors LLC lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 10.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,094,571 shares of the biopharmaceutical company’s stock after buying an additional 104,687 shares during the quarter. ProShare Advisors LLC’s holdings in Pfizer were worth $26,532,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. GKV Capital Management Co. Inc. purchased a new position in Pfizer during the first quarter worth about $27,000. Curio Wealth LLC lifted its holdings in Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 1,098 shares in the last quarter. Bayforest Capital Ltd purchased a new stake in shares of Pfizer in the first quarter valued at $28,000. Harbor Asset Planning Inc. purchased a new position in shares of Pfizer in the 2nd quarter worth $29,000. Finally, WPG Advisers LLC purchased a new stake in Pfizer during the 1st quarter worth $35,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the topic of a number of research analyst reports. The Goldman Sachs Group reiterated a “neutral” rating and set a $26.00 price objective on shares of Pfizer in a research note on Wednesday, November 5th. UBS Group restated a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Morgan Stanley dropped their price target on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research note on Friday, October 10th. Bank of America increased their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $28.18.

Pfizer Stock Up 4.5%

Shares of PFE stock opened at $25.49 on Wednesday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The firm’s fifty day moving average price is $24.75 and its two-hundred day moving average price is $24.41. The firm has a market capitalization of $144.93 billion, a P/E ratio of 13.56, a PEG ratio of 0.81 and a beta of 0.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is presently 100.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.